Single intravenous injection of plasmid DNA encoding human paraoxonase-1 inhibits hyperlipidemia in rats

Biochem Biophys Res Commun. 2010 Jun 25;397(2):257-62. doi: 10.1016/j.bbrc.2010.05.095. Epub 2010 May 24.

Abstract

Paraoxonase-1 (PON1, EC 3.1.8.1) is a high-density lipoprotein (HDL)-associated antioxidant enzyme, and its activity correlates negatively with the level of plasma low-density lipoprotein cholesterol (LDL-C) and triglyceridemia (TG). In this study, we examined the therapeutic effect of plasmid DNA containing the human PON1 gene (pcDNA/PON1) in hyperlipidemic model rats. The rats were fed a high-fat and high-cholesterol diet for 25 days to produce a hyperlipidemic animal model. Single intravenous injection of pcDNA/PON1 into model rats prevented dyslipidemia and hepatic lipid accumulation. The mechanisms of pcDNA/PON1 in treating hyperlipidemia were associated with increases of serum antioxidant PON1 and SOD activities, and with reduction of the levels of total cholesterol (TC), LDL-C and TG. The results suggest the potential therapeutic effect of pcDNA/PON1 on hyperlipidemia.

MeSH terms

  • Animals
  • Aryldialkylphosphatase / blood
  • Aryldialkylphosphatase / genetics*
  • Cholesterol, LDL / blood
  • DNA / administration & dosage*
  • Genetic Therapy / methods*
  • Humans
  • Hyperlipidemias / therapy*
  • Injections, Intravenous
  • Liver / metabolism
  • Male
  • Plasmids / administration & dosage
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase / blood
  • Triglycerides / blood

Substances

  • Cholesterol, LDL
  • Triglycerides
  • DNA
  • Superoxide Dismutase
  • Aryldialkylphosphatase
  • PON1 protein, human